Skip to content
Atlas Research Compounds

Bioregulatory peptides

Pinealon

A short synthetic tripeptide studied in bioregulation models.

Evidence
Preclinical
Literature
Limited preclinical literature
Family
Short peptide bioregulator

Overview

Pinealon is described in a relatively small body of literature on short peptide bioregulators. Much of the work is preclinical or hypothesis-generating, making independent replication and precise target identification central open questions.

Evidence maturity

Evidence score1/5

Preclinical foundation

The score summarizes evidence maturity, not safety, effectiveness, or suitability for any use.

Mechanism summary

Proposed as a short peptide bioregulator; direct molecular targets and independent replication remain limited.

Research category
Bioregulators
Editorial status
Published

Evidence synthesis

Structured evidence summary

Human studies
2
Animal studies
4
In vitro records
2
Review records
2
Abstract extracted
5
Metadata verified
5

Evidence strength

Limited translational

Confidence

Low confidence

Major findings

  • The verified set centers on short-peptide bioregulator, EDR, aging, oxidative-stress, and neural-context publications.
  • Atlas frames Pinealon as a limited bioregulator research cluster rather than a generalized healthy-aging claim.

Major limitations

  • Human evidence remains sparse relative to the number of mechanistic and preclinical records.
  • Several records are older or clustered by research tradition, making independent replication a key editorial question.

Counts are generated from verified PubMed records. Findings above are evidence-map observations, not clinical recommendations or inferred study outcomes. See the scoring methodology.

Scoring methodology

Evidence strength, quality, and confidence

Evidence strength

Compound-level strength is based on the verified study mix: human records, animal records, review or synthesis records, and extraction depth. It describes evidence maturity only.

Study quality

Study-level quality is not assessed for metadata-only records. Abstract-extracted records are rated from study design and extraction depth, not from unreviewed full-text claims.

Confidence

Confidence is capped when records remain metadata verified. Atlas does not raise confidence by counting citations without extracting endpoints, comparators, duration, and limitations.

Workflow states are `METADATA_VERIFIED`, `ABSTRACT_EXTRACTED`, `FULLTEXT_REVIEWED`, and `EDITORIAL_APPROVED`. Because full-text review is not available in this phase, no study is promoted to full-text or editorial-approved status.

Research timeline

Evidence stages describe maturity, not a chronological promise of development.

  1. Identity and target

    Documented

    The compound identity or proposed target is described in research literature.

  2. Preclinical research

    Emerging

    Preclinical support is limited, unclear, or not yet curated.

  3. Human research

    Not established

    A reliable human evidence base has not been established in this catalog.

  4. Independent synthesis

    Limited

    Independent replication and synthesis remain important evidence gaps.

Open research questions

  1. 01What direct molecular binding partners have been validated?
  2. 02Can reported effects be reproduced outside originating laboratories?
  3. 03What exposure levels are biologically plausible?

Literature starting points

These links support further review; inclusion is not an endorsement of every indexed conclusion.

  1. 01

    Short peptide bioregulator literature index

    PubMed, U.S. National Library of Medicine · Database

    Open source
  2. 02

    Atlas internal research database

    Internal Research Database · 2026 · Database

    Open source

Phase 2 study database

10 verified publications

Search all studies →
2020EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's DiseaseGrade C2015Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermiaGrade C2015[EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION].Grade B2014Short peptides stimulate serotonin expression in cells of brain cortexGrade D2014[Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats in model of sharp hypoxic hypoxia with Cortexin and Pinealon].Grade B

Deep research cluster

Explore Pinealon by evidence question

MechanismMechanistic pathways reported in verified publications, separated from clinical inference.Human studiesVerified human publications, study designs, findings, and explicit limitations.Animal studiesPreclinical animal models and the boundaries on translating their results.Safety evidenceWhat the verified publication set can and cannot establish about safety.Research historyA publication timeline built only from verified study records.ComparisonsContextual links to related compounds and existing structured comparisons.

Related comparisons

Pinealon vs. CortagenPinealon vs. SemaxSemax vs. PinealonSelank vs. PinealonPinealon vs. DSIPNoopept vs. Pinealon

Continue the research map

Related content

CompoundCortagenCompoundSemaxCompoundSelankVerified studyEDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's DiseaseVerified studyPinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermiaVerified study[EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION].ComparisonPinealon vs. CortagenComparisonPinealon vs. SemaxComparisonSemax vs. PinealonComparisonSelank vs. PinealonComparisonPinealon vs. DSIPComparisonNoopept vs. PinealonTopic hubCognitionTopic hubLongevityTopic hubSleepTopic hubNeuroprotectionTopic hubHealthy AgingTopic hubPeptide Research